Shares in 4DMedical Limited (ASX:4DX) fell 6.22% to A$4.07 on 5 October 2026. The medical technology company's stock was among the weaker performers on the ASX for the day. Individual session price movements in healthcare technology stocks reflect a combination of sector sentiment, market conditions and company-specific developments.

Company Update

Amid the day's trading backdrop, 4DMedical Limited (ASX:4DX) published its FY26 Annual Report, covering the twelve months ended 30 June 2026. The report highlighted Operating Revenue of $7.1 million, up 21% on FY25, with total income of $14.6 million including $7.5 million in other income. The year was marked by FDA clearance and CMS reimbursement for CT:VQ™, the company's next-generation lung imaging product, and a commercial distribution agreement with Philips.

Business Model and Operational Footprint

4DMedical Limited is an Australian medical technology company delivering next-generation cardiopulmonary imaging. Its core technology uses a software-as-a-service model to provide ventilation and perfusion information from standard CT scans, enabling non-invasive lung function assessment.

The company's flagship legacy product, XV LVAS™ (Lung Ventilation Analysis Software), provides ventilation imaging. CT:VQ™ is the company's breakthrough product providing both ventilation and perfusion imaging without contrast agents. 4DMedical operates across the Americas, Europe and the Australia/New Zealand region, with 540 active sites globally as at FY26. In FY26, the company acquired contextflow, expanding its European footprint.

Sector Context

Pulmonary function assessment traditionally relies on nuclear medicine-based ventilation-perfusion (V/Q) scanning, a procedure that involves radioactive tracers, specialist nuclear medicine facilities and significant logistical complexity. CT:VQ™ is positioned as the world's first non-contrast V/Q imaging solution, removing many barriers inherent in traditional nuclear V/Q scans and enabling broader access across CT-equipped hospitals. The grant of CMS reimbursement in the United States is a significant commercial milestone, making the product financially accessible for Medicare-certified hospitals and their patients.

The Philips distribution agreement provides 4DMedical with a commercial channel into Philips' extensive hospital relationships, including the U.S. Department of Veterans Affairs network.

The Announcement

The FY26 Annual Report, released in October 2026, detailed the following key developments. Operating revenue was $7.1 million, up 21% versus FY25. Total income was $14.6 million. Over 344,000 structural and functional lung scans were performed across 540 sites during FY26, up 77% on FY25. The company received FDA clearance and CMS reimbursement for CT:VQ™, with approximately US$10 million in customer orders noted. CT:VQ™ has received regulatory clearance in the U.S., Europe, UK, Canada and Australia.

The Philips Partnership provides a commercial distribution channel for CT:VQ™, particularly targeting the VA system and private clinics. The Acquisition of contextflow expanded 4DMedical's European commercial presence and pharmaceutical partnership engagement. The company's FY27 outlook noted the scale-up from one million scans per annum toward five million scans per annum as a key growth objective.

Growth Catalysts

CMS reimbursement in the United States opens the CT:VQ™ commercial opportunity across more than 4,000 Medicare-certified hospitals. The Philips distribution agreement provides channel Leverage that individual sales teams alone could not replicate. CT:VQ™ clearances across multiple major markets allow parallel commercial development. Growing scan volumes at existing sites indicate increasing clinical adoption. The acquisition of contextflow adds pharmaceutical industry engagement in Europe.

Risks

Revenue at $7.1 million remains early-stage relative to the commercial opportunity described by the company. Converting site activations into high-volume clinical use depends on clinician adoption and workflow integration. Other income of $7.5 million included government grants and similar items; sustainable revenue growth depends on the commercial revenue line. Competition from existing nuclear V/Q procedures and any new entrants in CT-based lung function analysis represents a market risk. Clinical adoption timelines in healthcare can extend beyond initial commercial projections.